Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite
March 26 2018 - 3:00AM
Business Wire
Abzena plc, the life sciences group providing services and
technologies to enable the design, development and manufacture of
biopharmaceutical products, has announced the completion of the
facility remodelling for its new antibody-drug conjugate (ADC) GMP
manufacturing suite at its Bristol, Pennsylvania site.
The facility is being equipped with state-of-the-art Sartorius
and GE equipment for single use scale-up, manufacture and
purification processes. The environmentally controlled suite will
enable Abzena to produce antibody-drug conjugates (ADCs) for
preclinical and early phase clinical studies. The suite is a
significant part of Abzena’s integrated ADC capabilities for the
design, development and manufacture of ADCs.
The facility and equipment verification and qualification for
this ADC GMP manufacturing suite is currently underway, and
scheduled for completion around the end of the second quarter of
2018.
Completion of the GMP ADC manufacturing suite construction marks
a key point in Abzena’s programme to significantly expand the
Group’s integrated ADC chemistry solutions. This ADC manufacturing
suite complements the existing GMP manufacturing capability for the
scale-up and manufacture of highly potent payload-linker
constructs, and the upgrading and expansion of Abzena’s biologics
process development and manufacturing capabilities in San Diego.
The plans are on track for the initial relocation for Abzena’s
biologics manufacturing process and analytical development groups
into the new San Diego facility during April 2018.
Abzena has existing client process development programmes
scheduled for the Bristol ADC manufacturing facility including an
ADC utilising the Group’s proprietary ThioBridge™ conjugation
technology and another that has benefitted from an integrated
programme comprising cell line development, antibody production and
development and manufacture of the ADC product including the
linker-payload reagent.
Sanjeevani Ghone, Vice President and Site Head, Abzena,
Bristol PA said:
“The completion of this facility is a significant step in
realising Abzena’s vision of being a full service and technology
provider for the design, development and manufacture of ADCs. Our
recent contracts are a testament to our client’s confidence in our
expertise and experience in this field.”
-Ends-
About Abzena
Abzena provides proprietary technologies and complementary
services to enable the development and manufacture of
biopharmaceutical products.
The term ‘ABZENA Inside’ is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena
has the potential to earn future licence fees, milestone payments
and/or royalties on ‘ABZENA Inside’ products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
- Biology research studies, including
immunogenicity assessment of candidate biopharmaceutical products
and bioassay development;
- Protein engineering to create humanized
antibodies and deimmunised therapeutic proteins;
- Cell line development for the
manufacture of recombinant proteins and antibodies;
- Contract process development and GMP
manufacture of biopharmaceuticals, including monoclonal antibodies
and recombinant proteins for preclinical and clinical studies;
- Contract synthetic chemistry and
bioconjugation research services, focused on ADCs;
- Proprietary site-specific conjugation
technologies and novel payloads for ADC development;
- GMP manufacturer of ADC linkers,
payloads & combined linker-payloads; and.
- GMP analytical services for
biopharmaceutical manufacturing projects
For more information, please see www.abzena.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180326005134/en/
Abzena+441223903498 (Cambridge, UK)+12157883603 (Bristol
PA, USA)+18585504049 (San Diego, USA)orSanjeevani Ghone, VP &
Site Head, Abzena Bristol PAsanjeevani.ghone@abzena.comorSven Lee,
Chief Business Officersven.lee@abzena.comorMin Park, Global Head of
Marketingmin.park@abzena.comorJoesph Reeds, Marketing
Managerjoseph.reeds@abzena.comorInstinctif PartnersMelanie
Toyne Sewellabzena@instinctif.com+442074572020
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024